

Non-Small Cell Lung Cancer

Reference Number: F4773
Date of Response: 26/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:-

- Afatinib – **0 patients**
- Alectinib – **6 patients**
- Amivantamab – **0 patients**
- Atezolizumab monotherapy – *** patients**
- Atezolizumab with chemotherapy – *** ≤5 patients**
- Brigatinib – **0 patients**
- Ceritinib – **0 patients**
- Crizotinib – *** ≤5 patients**
- Dacomitinib – **0 patients**
- Dabrafenib with Trametinib – *** ≤5 patients**
- Durvalumab – *** ≤5 patients**
- Erlotinib – *** ≤5 patients**
- Gefitinib – **0 patients**
- Lorlatinib – *** patients**
- Mobocertinib – **0 patients**
- Nintedanib with Docetaxel – *** ≤5 patients**
- Nivolumab – **0 patients**
- Osimertinib – **17 patients**
- Pembrolizumab monotherapy – **20 patients**
- Pembrolizumab with chemotherapy – **0 patients (No adjuvant patients)**
- Pemetrexed with Carboplatin/Cisplatin – **5 patients**
- Sotorasib – **0 patients**
- Tepotinib – **0 patients**
- Vinorelbine with Carboplatin/Cisplatin – **8 patients**
- Any other active systemic anti-cancer therapy (SACT) – **15 patients**
- Palliative care only – **0 patients**

* - ≤5 Low number suppressed to protect patient identity.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.